{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:55:24Z","timestamp":1789725324922,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advances in DNA sequencing technology have created a wealth of information regarding the genomic landscape of prostate cancer. It had been thought that BRCA1 and BRCA2 mutations were associated with only a small fraction of prostate cancer cases. However, recent genomic analysis has revealed that germline or somatic inactivating mutations in BRCA1 or BRCA2, or other genes involved in the homologous recombination (HR) pathway of DNA repair collectively occur in as much as 20%\u201325% of advanced prostate cancers. A synthetic lethal therapeutic approach using poly(ADP-ribose) polymerase inhibitor therapy has been developed for BRCA mutant- and HR deficient-related cancers (those with \u201cBRCAness\u201d) and is being studied in multiple clinical trials. This article discusses the current understanding of the genomic landscape of prostate cancer, focusing on the occurrence of DNA repair mutations and the therapeutic opportunities that this presents.<\/jats:p>","DOI":"10.1634\/theoncologist.2016-0135","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T01:54:01Z","timestamp":1466214841000},"page":"940-945","source":"Crossref","is-referenced-by-count":30,"title":["DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities"],"prefix":"10.1093","volume":"21","author":[{"given":"Mallika","family":"Dhawan","sequence":"first","affiliation":[{"name":"Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[{"name":"Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"key":"2021122309525003200_B1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"2021122309525003200_B2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2021122309525003200_B3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer [published correction appears in Cell 2015;162(2):454]","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2021122309525003200_B4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"2021122309525003200_B5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"2021122309525003200_B6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","article-title":"Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer [published correction appears in Cancer Cell 2013;23(4):557]","volume":"19","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"key":"2021122309525003200_B7","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309525003200_B8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122309525003200_B9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2021122309525003200_B10","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"2021122309525003200_B11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"BioEssays"},{"key":"2021122309525003200_B12","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/bi0003442","article-title":"Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1","volume":"39","author":"Dantzer","year":"2000","journal-title":"Biochemistry"},{"key":"2021122309525003200_B13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2021122309525003200_B14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2021122309525003200_B15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309525003200_B16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122309525003200_B17","volume-title":"Clinicatrials.gov"},{"key":"2021122309525003200_B18","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS14-S3-01","article-title":"The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1\/2 breast cancer (CRUK\/07\/012) [abstract S3-01]","volume-title":"Presented at the 2014 San Antonio Breast Cancer Symposium","author":"Tutt"},{"key":"2021122309525003200_B19","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122309525003200_B20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122309525003200_B21","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309525003200_B22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","article-title":"Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP","volume":"12","author":"Chao","year":"2014","journal-title":"Mol Cancer Res"},{"key":"2021122309525003200_B23","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"2021122309525003200_B24","doi-asserted-by":"crossref","first-page":"e64268","DOI":"10.1371\/journal.pone.0064268","article-title":"Classifications within molecular subtypes enables identification of BRCA1\/BRCA2 mutation carriers by RNA tumor profiling","volume":"8","author":"Larsen","year":"2013","journal-title":"PLoS One"},{"key":"2021122309525003200_B25","doi-asserted-by":"crossref","first-page":"djt335","DOI":"10.1093\/jnci\/djt335","article-title":"Identification and validation of an anthracycline\/cyclophosphamide-based chemotherapy response assay in breast cancer","volume":"106","author":"Mulligan","year":"2014","journal-title":"J Natl Cancer Inst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/8\/940\/41875033\/oncolo_21_8_940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/8\/940\/41875033\/oncolo_21_8_940.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:19:13Z","timestamp":1640319553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/8\/940\/6401481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,6,17]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0135","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8,1]]},"published":{"date-parts":[[2016,6,17]]}}}